Director/PDMR Shareholding

PROTEOME SCIENCES plc ("Proteome Sciences" or the "Company") PRESS RELEASE Issue of Equity, Directors' Dealings and Total Voting Rights The Company has issued and allotted, subject to admission, 1,258,124 new ordinary shares of 1p each ("the Shares") following the exercise of options by Christopher Pearce, Chief Executive Officer, and James Malthouse, Finance Director. The details of the options exercised are as follows: Name Date of exercise No. of options exercised Exercise price Christopher Pearce 9 April 2008 450,000 37p Christopher Pearce 9 April 2008 433,124 45p James Malthouse 9 April 2008 375,000 37p Following the exercise of the options, Christopher Pearce holds 6,538,075 ordinary shares, representing 4.93 per cent of the issued share capital. James Malthouse holds 625,000 shares, representing 0.47 per cent of the issued share capital. The Shares will rank equally with the existing ordinary shares of the Company. Application has been made for the Shares to be admitted to AIM. Trading is expected to commence on AIM on 16 April 2008 ("Admission"). For the purposes of the Financial Services Authority's Disclosure and Transparency Rules, following Admission the total number of ordinary shares of Proteome Sciences in issue will be 132,723,571 with each share holding one voting right. The Company does not hold any ordinary shares in Treasury. Therefore, the total number of ordinary shares with voting rights will be 132,723,571. The above figure of 132,723,571 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company. Ends Proteome Sciences plc Christopher Pearce James Malthouse Chief Executive Officer Finance Director christopher.pearce@proteomics.com james.malthouse@proteomics.com Tel: +44 (0)1932 865065 Nominated Adviser Landsbanki Securities (UK) Limited Gareth Price / Thilo Hoffman Tel: +44 (0)20 7426 9000
UK 100

Latest directors dealings